Celyad (CYAD)
(Delayed Data from NSDQ)
$0.47 USD
0.00 (0.00%)
Updated May 18, 2023 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
CYAD 0.47 0.00(0.00%)
Will CYAD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CYAD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYAD
Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know
CYAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CYAD
Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights
Celyad Oncology announces intention to terminate SEC reporting obligations
Celyad Oncology Announces Intention to Terminate SEC Reporting Obligations